Preparation method of paeonia lactiflora and liquorice decoction nano dosage form and application of paeonia lactiflora and liquorice decoction nano dosage form in non-alcoholic fatty liver disease

Nanogenerating peony glycyrrhizic acid through nanotechnology solves the problems of low bioavailability and poor targeting in the treatment of non-alcoholic fatty liver, and achieves significant efficacy and safety and effectiveness in non-alcoholic fatty liver. therapeutic effect.

CN118975993APending Publication Date: 2024-11-19GUANGDONG MEDICAL UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411107535.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-19

Smart Images

  • Figure CN118975993A_ABST
    Figure CN118975993A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a paeoniflorin and glycyrrhizic acid nano dosage form and application of the paeoniflorin and glycyrrhizic acid nano dosage form in non-alcoholic fatty liver disease, and the preparation method comprises the following steps: step 1, weighing paeoniflorin, glycyrrhizic acid and PLGA-PEG, dispersing the paeoniflorin, glycyrrhizic acid and PLGA-PEG in dichloromethane, and adding into a high-pressure homogenizer for emulsification; 2, dissolving 0.1-3% of PVA as an external water phase, and adding a glacial acetic acid solution and chitosan at the same time; 3, quickly adding the emulsion obtained in the step 1 into an external water phase, oscillating, and emulsifying in a high-pressure homogenizer; and step 4, adding mannose into the obtained emulsion, then freeze-drying, and storing in a refrigerator at 4 DEG C. The invention can be used for protecting, preventing and treating non-alcoholic steatohepatitis and liver injury, not only can improve the bioavailability of the medicine and enhance the targeting property of the medicine, but also is expected to reduce adverse reactions and toxic and side effects, and provides a new research thought and method for the modern development of traditional Chinese medicines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of functional health foods, and in particular to a preparation method of a Shaoyao Gancao decoction nano dosage form and an application of the nano dosage form in non-alcoholic fatty liver disease. Background Art

[0002] Nonalcoholic fatty liver disease is an emerging health problem worldwide, and its incidence has increased significantly in the past two decades. NAFLD covers a spectrum of diseases from simple hepatic steatosis to nonalcoholic steatohepatitis, characterized by hepatocellular damage, persistent hepatitis and fibrosis, and ultimately progressing to cirrhosis and hepatocellular carcinoma (HCC). Simple steatosis is a relatively benign disease, and the pathological and biological process of its evolution to NASH is complex and multi-stage. It involves multiple pathogenic factors such as fat accumulation, lipotoxicity, inflammation, oxidative stress, and apoptosis. There are currently no approved drugs for the treatment of NAFLD, and most of the existing clinical therapeutic drugs have poor selectivity, low distribution, instability, and drug toxicity. Therefore, there is an urgent need for efficient drugs and strategies for the treatment of NAFLD in the clinic.

[0003] Traditional Chinese medicine is a treasure of the Chinese nation and an important part of modern medicine. Traditional Chinese medicine has a long history of treating diseases. Many Chinese medicines are both medicinal and edible, which has been verified by a long history. Among them, the classic prescription "Peony and Licorice Decoction" is a basic prescription for softening the liver, relieving urgency and relieving pain. It comes from "Treatise on Febrile and Miscellaneous Diseases: Differentiation of Taiyang Disease Pulse and Symptoms and Treatment". It was designed by Zhang Zhongjing to treat typhoid fever with deficiency, sweating and loss of yang, and yang recovery after cold feet and foot cramps. It is composed of only two herbs, white peony and licorice. It is a representative prescription for sour and sweet to transform yin, regulate liver and spleen. In the prescription, white peony is sour and cold, enters the liver and spleen meridians, and is good at astringing liver yin to nourish blood, regulate liver and spleen, soften liver and relieve pain; licorice is sweet and flat in nature, good at relieving urgency and relieving pain, can enter the middle jiao and has the power to nourish spleen and replenish qi.

[0004] However, most traditional Chinese medicine preparations show the characteristics of overall regulation and multi-target in the treatment of diseases. It is precisely because of the complexity of this ingredient that its material basis is unclear, its mechanism of action is unclear, and its absorption, distribution, and metabolism mechanism in the human body are unclear. This also makes it difficult for the "therapeutic effect" of traditional Chinese medicine to directly hit the lesions. In addition, many active ingredients of traditional Chinese medicine, such as glycyrrhizic acid, show high anti-inflammatory and antioxidant activity at the cellular level, but due to its poor water solubility, low bioavailability, off-target and difficulty in entering cells, its efficacy is greatly limited.

[0005] Compared with traditional Chinese medicine, nano-TCM can not only improve the bioavailability of drugs and enhance their targeting, but also is expected to reduce adverse reactions and toxic side effects, providing new research ideas and methods for the modernization of TCM. Summary of the invention

[0006] In view of this, the present invention provides a method for preparing a Shaoyao Gancao Decoction nano dosage form and its application in non-alcoholic fatty liver disease.

[0007] A method for preparing a Shaoyao Gancao Tang nano dosage form, characterized in that it comprises the following steps:

[0008] Step 1: Weigh paeoniflorin, glycyrrhizic acid and PLGA-PEG, disperse them in dichloromethane, and add a high-pressure homogenizer for emulsification;

[0009] Step 2: Dissolve 0.1-3% PVA as the external aqueous phase, and add glacial acetic acid solution and chitosan;

[0010] Step 3: quickly add the emulsion obtained in step 1 to the external aqueous phase, shake it, and emulsify it in a high-pressure homogenizer;

[0011] Step 4: Mannose was added to the obtained emulsion, which was then freeze-dried and stored in a refrigerator at 4°.

[0012] Preferably, in step 1, the mass of paeoniflorin is 100-200 mg.

[0013] Preferably, the mass of glycyrrhizic acid in step 1 is 100-200 mg.

[0014] Preferably, in step 1, the mass of PLGA-PEG is 2 to 5 g.

[0015] Preferably, in step 1, the volume of dichloromethane is 10 mL.

[0016] Preferably, in step 2, the deacetylation degree of PVA is 85% to 95%.

[0017] Preferably, in step 2, the concentration of chitosan is 0.1-2%, and the volume is 50 mL;

[0018] Preferably, in step 4, the concentration of mannose is 5%.

[0019] Preferably, when used, the nano preparation is added to an auxiliary material or edible gel or pectin for oral administration.

[0020] A method for preparing a nano dosage form of Shaoyao Gancao Decoction and its application in non-alcoholic fatty liver disease.

[0021] Compared with the prior art, the present invention has achieved the following technical effects:

[0022] (1) Paeoniflorin and glycyrrhizic acid have low water solubility and are rapidly metabolized in the human gastrointestinal tract, resulting in poor bioavailability. However, the nanoemulsification of the present invention significantly improves the water solubility, cellular absorption, and bioavailability of poorly soluble small molecule drugs;

[0023] (2) The chitosan used in the present invention is a cationic polymer of natural origin, which has good biocompatibility, mucosal adsorption, biodegradability and low immunogenicity;

[0024] (3) After modification with chitosan and mannose, the nanoparticles significantly enhance the intestinal cell adsorption and intestinal macrophage targeting;

[0025] (4) In the present invention, nano-TCM can not only improve the bioavailability of drugs and enhance their targeting, but also reduce adverse reactions and toxic side effects, providing new research ideas and methods for the development of the modernization of TCM;

[0026] (5) The present invention can be used for the protection and prevention of non-alcoholic fatty hepatitis and liver damage. The nano-sized "peonidin-glycyrrhizic acid" is safe and effective for oral or parenteral administration. Oral medication can be made into any conventional dosage form, such as tablets, capsules, powders, granules, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 The present invention provides a preparation method of Shaoyao Gancao Tang nano dosage form and a flow chart of the preparation of a traditional Chinese medicine nanoemulsion for use in non-alcoholic fatty liver disease.

[0028] Figure 2 This is a characterization diagram of a preparation method of a nano dosage form of Shaoyao Gancao Tang and a nano traditional Chinese medicine emulsion for use in non-alcoholic fatty liver disease according to the present invention;

[0029] Figure 3 A diagram of a high-fat diet-induced non-alcoholic fatty liver model of mice, showing a method for preparing a nano dosage form of Shaoyao Gancao Tang and its application in non-alcoholic fatty liver disease;

[0030] Figure 4 , Figure 5 , Figure 6 This is a diagram showing the experimental results of a preparation method of a Shaoyao Gancao Tang nano dosage form and its application in non-alcoholic fatty liver disease;

[0031] Figure 7 This is a preparation method of a nano dosage form of Shaoyao Gancao Decoction and its application in non-alcoholic fatty liver disease. Different drug intervention groups are used to analyze the pathological sections of liver tissues in mice with non-alcoholic fatty liver disease (NAFLD) model induced by a high-fat diet. DETAILED DESCRIPTION

[0032] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] like Figure 1 As shown in the figure, it is a flow chart for preparing the nanoemulsion of traditional Chinese medicine of the present invention. The present invention discloses a method for preparing a nano dosage form of Shaoyao Gancao Tang, comprising the following steps:

[0034] Step 1: Weigh 100-200 mg of paeoniflorin, 100-200 mg of glycyrrhizic acid and 2-5 g of PLGA-PEG, disperse them in 10 mL of dichloromethane, and add a high-pressure homogenizer for emulsification;

[0035] Step 2: Dissolve 0.1-3% PVA (deacetylation degree is 85%-95%) as the external aqueous phase, and add glacial acetic acid solution and chitosan at the same time, the concentration of chitosan is 0.1-2%, and the volume is 50 mL;

[0036] Step 3: quickly add the emulsion obtained in step 1 to the external aqueous phase, shake it, and emulsify it in a high-pressure homogenizer;

[0037] Step 4: 5% mannose was added to the obtained emulsion, then freeze-dried and stored in a refrigerator at 4°.

[0038] like Figure 2 , which is a characterization diagram of the nano-TCM emulsion prepared by the present invention, wherein the ultraviolet absorption spectrum shows that the nano-preparation is successfully loaded with paeoniflorin and glycyrrhizic acid.

[0039] like Figure 3 As shown, it is a diagram of the non-alcoholic fatty liver model induced by high-fat diet in mice of the present invention. Six-week-old C57 / 6J mice were purchased, adaptively cultured for 2 weeks, and after 6 weeks of high-fat diet, the mice were divided into three groups: 1) The first group took normal saline orally twice a week; 2) The second group took the active ingredient of "Peony and Licorice Decoction" - a mixture of paeoniflorin-glycyrrhizic acid orally (dose: paeoniflorin 1mg / kg, glycyrrhizic acid 1mg / kg), 3) The third group took nano-sized "peoniflorin-glycyrrhizic acid" orally (dose: paeoniflorin 1mg / kg, glycyrrhizic acid 1mg / kg, calculated by the drug content encapsulated in the nanoparticles). After 8 weeks of drug intervention, the mice were anesthetized and killed, and blood, liver, and major tissues and organs were collected for analysis.

[0040] like Figure 4As shown, since the active ingredients of traditional Chinese medicine have no fluorescence themselves, indocyanine green (ICG) is co-loaded into nanoparticles with the active ingredients of traditional Chinese medicine as fluorescent markers. After mice were induced to have NAFLD by a high-fat diet for 8 weeks, fluorescent imaging of mice and major organs was performed after oral administration of active ingredients of traditional Chinese medicine or nano-active ingredients of traditional Chinese medicine for different periods of time. The results showed that after 24 hours and 36 hours of oral administration, the active ingredient group of traditional Chinese medicine had been metabolized or excreted, with very little retention in the intestine, while the nano-active drug group was still retained in the intestine. This shows that the nano-structure can significantly prolong the retention and release of traditional Chinese medicine components in the body. After 24 hours of oral administration, the drug can enter the liver, and after 36 hours, the enrichment and retention of nano-active traditional Chinese medicine components in the liver increased significantly.

[0041] like Figure 5 As shown, after oral administration twice a week, the active ingredient paeoniflorin-glycyrrhizic acid in "Peony and Licorice Decoction" can significantly inhibit the body weight of the high-fat diet obesity model of mice and inhibit liver weight gain. Among them, the nano-sized "peoniflorin-glycyrrhizic acid" oral intervention group had the most significant therapeutic effect.

[0042] like Figure 6 As shown in the figure, after oral administration twice a week, the active ingredient of "Shaoyao Gancao Tang" paeoniflorin-glycyrrhizic acid can significantly reduce liver accumulation and improve liver function. (A) Photos of livers in different drug intervention groups; (BC) Levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the serum of mice in different drug intervention groups, where: *p<0.05, **p<0.01, ***p<0.001 compared with the model group (normal saline intervention group). Mice were fed a high-fat diet for 6 weeks and oral administration for 8 weeks. After fasting for 12 hours but not water, blood was collected and sacrificed. After the blood was placed at room temperature for 1 hour, it was centrifuged at 3000 rpm and 4℃ for 10 minutes, and the upper serum was collected and packaged. The activity values ​​of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse plasma were detected by kits. The enzyme activity values ​​of the model group increased significantly compared with the normal group; after 8 weeks of oral administration, the activity values ​​of ALT and AST in the liver decreased compared with the model group. The results showed that paeoniflorin-glycyrrhizic acid had a certain therapeutic effect on the increase of ALT and AST activity values ​​in the serum of mice caused by liver damage, and the nano-drug had the most significant effect. Oral administration of the active ingredients of Shaoyao Gancao Decoction had a certain preventive effect on the increase of AST activity values ​​in the serum of mice caused by liver damage.

[0043] like Figure 7As shown, the analysis of liver tissue pathological sections of mice with non-alcoholic fatty liver disease (NAFLD) model induced by high-fat diet in different drug intervention groups: (A) HE staining results of mouse liver tissue sections; (B) Oil red O staining results of mouse liver tissue sections. In the figure, it can be clearly observed that there is severe fat accumulation in the model group, while the drug-treated group can reduce the formation of liver fat droplets in NAFLD mice, and the nano-drug group has the most significant inhibitory effect.

[0044] The above description is only a preferred embodiment of the present invention and does not limit the technical scope of the present invention. Therefore, any slight modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention are still within the scope of the technical solution of the present invention.

Claims

1. A method for preparing a Shaoyao Gancao Decoction nano dosage form, characterized in that: The following steps are involved: Step 1: Weigh paeoniflorin, glycyrrhizic acid and PLGA-PEG, disperse them in dichloromethane, and add a high-pressure homogenizer for emulsification; Step 2: Dissolve 0.1-3% PVA as the external aqueous phase, and add glacial acetic acid solution and chitosan; Step 3: quickly add the emulsion obtained in step 1 to the external aqueous phase, shake it, and emulsify it in a high-pressure homogenizer; Step 4: Mannose was added to the obtained emulsion, which was then freeze-dried and stored in a refrigerator at 4°.

2. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In the step 1, the mass of paeoniflorin is 100-200 mg.

3. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: The mass of glycyrrhizic acid in step 1 is 100-200 mg.

4. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In the step 1, the mass of PLGA-PEG is 2 to 5 g.

5. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In step 1, the volume of dichloromethane is 10 mL.

6. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In the step 2, the deacetylation degree of PVA is 85% to 95%.

7. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In the step 2, the concentration of chitosan is 0.1-2%, and the volume is 50 mL.

8. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: In step 4, the concentration of mannose is 5%.

9. The method for preparing a Shaoyaogancao Decoction nano dosage form according to claim 1, characterized in that: When used, the nano preparation is added to auxiliary materials or edible gel or pectin and taken orally.

10. Use of the preparation method of Shaoyao Gancao Tang nano dosage form according to claim 1 in non-alcoholic fatty liver disease.

Citation Information

Cited By

  • Sodium alginate hydrogel embedded bionic nanoparticles as well as preparation method and application thereof

    CN119745903A

  • Fluorescence-labeled traditional Chinese medicine compound decoction nanoparticles and application thereof

    CN120983661A